Clinical Trial Update: A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study evaluating CAD106 and CNP520 versus placebo in individuals at risk for developing Alzheimer's disease was terminated; results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• CAD106
• CNP520

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Alzheimers Disease | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2021-07-08